Overdiagnosis of prostate cancer, linked to increased PSA testing, leads to unnecessary treatments and wasted healthcare resources, raising concerns about its impact on men’s quality of life.
The divergence between incident cases and deaths suggests that the intensity of PSA testing has been a critical driver for the increasing trends in prostate cancer across Europe.
Most countries experience sharp increases in prostate cancer diagnosis from 1990 to 2017, raising the question of whether population-wide screening programs are beneficial or harmful.
While prostate cancer mortality has generally decreased, the concurrent rise in diagnoses highlights the pressing need to address overdiagnosis, particularly in relation to PSA testing.
Collection
[
|
...
]